Nature Communications (Dec 2021)
Paracrine FGFs target skeletal muscle to exert potent anti-hyperglycemic effects
- Lei Ying,
- Luyao Wang,
- Kaiwen Guo,
- Yushu Hou,
- Na Li,
- Shuyi Wang,
- Xingfeng Liu,
- Qijin Zhao,
- Jie Zhou,
- Longwei Zhao,
- Jianlou Niu,
- Chuchu Chen,
- Lintao Song,
- Shaocong Hou,
- Lijuan Kong,
- Xiaokun Li,
- Jun Ren,
- Pingping Li,
- Moosa Mohammadi,
- Zhifeng Huang
Affiliations
- Lei Ying
- School of Pharmaceutical Sciences, Wenzhou Medical University
- Luyao Wang
- School of Pharmaceutical Sciences, Wenzhou Medical University
- Kaiwen Guo
- School of Pharmaceutical Sciences, Wenzhou Medical University
- Yushu Hou
- School of Pharmaceutical Sciences, Wenzhou Medical University
- Na Li
- School of Pharmaceutical Sciences, Wenzhou Medical University
- Shuyi Wang
- Department of Cardiology and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University
- Xingfeng Liu
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College
- Qijin Zhao
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College
- Jie Zhou
- School of Pharmaceutical Sciences, Wenzhou Medical University
- Longwei Zhao
- School of Pharmaceutical Sciences, Wenzhou Medical University
- Jianlou Niu
- School of Pharmaceutical Sciences, Wenzhou Medical University
- Chuchu Chen
- School of Pharmaceutical Sciences, Wenzhou Medical University
- Lintao Song
- School of Pharmaceutical Sciences, Wenzhou Medical University
- Shaocong Hou
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College
- Lijuan Kong
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College
- Xiaokun Li
- School of Pharmaceutical Sciences, Wenzhou Medical University
- Jun Ren
- Department of Cardiology and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University
- Pingping Li
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College
- Moosa Mohammadi
- Department of Biochemistry & Molecular Pharmacology, New York University School of Medicine
- Zhifeng Huang
- School of Pharmaceutical Sciences, Wenzhou Medical University
- DOI
- https://doi.org/10.1038/s41467-021-27584-y
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 14
Abstract
Fibroblast growth factors are involved in systemic glucose homeostasis and of interest for developing therapies for type 2 diabetes and associated metabolic diseases. Here the authors identify paracrine FGF4 as an anti-hyperglycemic FGF, which targets skeletal muscle to upregulate the glucose transporter GLUT4 cell surface abundance.
